EUVIMEDEUVIMED entdecken
Crossref

Combination nanochemotherapy of brain tumor using polymeric nanoparticles loaded with doxorubicin and paclitaxel: An in vitro and in vivo study

Mohammad Reza Malekpour, Saereh Hosseindoost, Fatemeh Madani, Morteza Kamali, Masood Khosravani, Mahdi Adabi

European Journal of Pharmaceutics and Biopharmaceutics · 2023

DOI: 10.1016/j.ejpb.2023.11.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023. Verfasst von Mohammad Reza Malekpour und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma, Nanoparticles. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Tehran University of Medical Sciences and Health Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aims to overcome physiological barriers and increase the therapeutic index for the treatment of glioblastoma (GBM) tumors by using Paclitaxel (PTX) loaded Poly(lactic co-glycolic acid) nanoparticles (PTX-PLGA-NPs) and Doxorubicin (DOX) loaded Poly (lactic co-glycolic acid) nanoparticles (DOX-PLGA-NPs). The hydrodynamic diameter of nanoparticles (NPs) was characterized by dynamic light scattering (DLS) which was 94 ± 4 nm and 133 ± 6 nm for DOX-PLGA-NPs, and PTX-PLGA-NPs, respectively. The zeta potential for DOX-PLGA-NPs and PTX-PLGA-NPs were -15.2 ± 0.18 mV and -17.3 ± 0.34 mV, respectively. The cytotoxicity of PTX-PLGA-NPs and DOX-PLGA-NPs was augmented compared to DOX and PTX on C6 GBM cells. The Lactate dehydrogenase (LDH) tests for various formulations were carried out. The results indicated that the amount of released LDH was 262 ± 7.84 U.L-1 at the concentration of 2 mg/mL in the combination therapy, which was much higher than other groups (DOX-PLGA-NPs (210 ± 6.92 U.L-1), PTX-PLGA-NPs (201 ± 8.65 U.L-1), DOX (110 ± 9.81 U.L-1), PTX (95 ± 5.02 U.L-1) and PTX + DOX (67 ± 4.89 U.L-1)). MRI results of the combination therapy of PTX-PLGA-NPs and DOX-PLGA-NPs indicated that GBM tumor size decreased considerably compared to the other formulations. Also, combination therapy of PTX-PLGA-NPs and DOX-PLGA-NPs demonstrated a longer median survival of more than 80 days compared to PTX (38 days), DOX (37 days) and PTX + DOX (48 days), PTX-NPs (58 days) and DOX-NPs (62 days). The results of locomotion, body weight, rearing and grooming assays indicated that combination therapy of PTX-PLGA-NPs and DOX-PLGA-NPs had the most positive effect on the movements of rats compared to the other formulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGlioblastomaNanoparticlesRatsAnimalsPaclitaxelPolylactic Acid-Polyglycolic Acid CopolymerPolyglycolic AcidLactic AcidCell Line, TumorDoxorubicinGlycolates

Stichwörter der Autor:innen

DoxorubicinGlioblastomaMRINanoparticlePLGAPaclitaxel

Substanzen

PaclitaxelPolylactic Acid-Polyglycolic Acid CopolymerPolyglycolic AcidLactic AcidDoxorubicinglycolic acidGlycolates

Autor:innen und Institutionen

  • Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: drkhosravani@tums.ac.ir.
  • Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, I…

Förderung

  • Tehran University of Medical Sciences and Health Services

Zitieren

APA

Malekpour, M. R., Hosseindoost, S., Madani, F., Kamali, M., Khosravani, M., & Adabi, M. (2023). Combination nanochemotherapy of brain tumor using polymeric nanoparticles loaded with doxorubicin and paclitaxel: An in vitro and in vivo study. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.11.002

Vancouver

Malekpour MR, Hosseindoost S, Madani F, Kamali M, Khosravani M, Adabi M. Combination nanochemotherapy of brain tumor using polymeric nanoparticles loaded with doxorubicin and paclitaxel: An in vitro and in vivo study. European Journal of Pharmaceutics and Biopharmaceutics. 2023. doi:10.1016/j.ejpb.2023.11.002

BibTeX
@article{Malekpour2023,
  author = {Malekpour, Mohammad Reza and Hosseindoost, Saereh and Madani, Fatemeh and Kamali, Morteza and Khosravani, Masood and Adabi, Mahdi},
  title = {Combination nanochemotherapy of brain tumor using polymeric nanoparticles loaded with doxorubicin and paclitaxel: An in vitro and in vivo study},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2023},
  doi = {10.1016/j.ejpb.2023.11.002}
}
Kostenlos starten →